logo AIRI
News archive
"Biotechnology companies in Italy" report 2020 Priority Technologies

"Biotechnology companies in Italy" report 2020

Since 2003, Assobiotec has published an annual report on biotechnology in Italy which, thanks to the now consolidated collaboration with ENEA, offers an updated snapshot of the numbers of the national sector and of research and development activities.

The BioInItaly Report 2020 takes an updated snapshot of the numbers of the national sector and of the research and development activities, continuing the in-depth analysis in two macro chapters: the area of ​​health, made up of diagnostics, vaccination prevention and therapeutic solutions, and the bioeconomy, which crosses agriculture and animal husbandry, industry and the environment.

The appendix "Biotech vs Covid-19", which is an integral part of the 2020 biotech companies report, has been dedicated to the response given by the sector to the coronavirus emergency and the effects caused on businesses by the SARS-CoV-2 pandemic.
Research and development activities
Research and development activities are analyzed on the basis of the following topics:

The position of Italy;
Technology transfer;
Technology Transfer Offices in Italy: initiatives and strategies for strengthening;
Science parks, incubators and accelerators to support new entrepreneurship;
Territorial specializations; Analysis of technological areas and application sectors;
Territorial specialization in the main technological areas;
Analysis of financing sources;
The numbers of Italian biotech and related research and development activities were examined in depth in the area of ​​health (diagnostics, vaccination prevention and therapeutic solutions) and the bioeconomy (agriculture and animal husbandry, industry and the environment).

In research and development activities, Italy's position stands out for: excellent, but underpowered research.

Based on the data, the Italian biotech sector confirms itself as a growing sector with a population of companies that has been consolidating in numerical terms, but which should strengthen in terms of size also in order to improve its competitiveness at an international level. The intensity of research and development activities remains strong, with excellence in all sectors of biotechnology application.

Companies dedicated to biotech R&D or which commit 75% or more of their research costs intra-muros in biotech activities, there are 208, of which 92% are Italian-owned: a figure that highlights how biotechnologies have opened up important opportunities in the research phase early-stage within the pharmaceutical supply chain.

There are 208 biotechnological companies operating in the industry and environment area, equal to 30% of the national total. They offer tools to optimize the transformation of biomass into eco-sustainable bio-products and third generation biofuels or to improve the yield and environmental sustainability of traditional production processes.

The turnover of companies active in the industry and environment area exceeds 2 billion euros.
In the period 2014-2018, the rates of increase in investments in biotech R&D intra-muros have had particularly strong dynamics in industrial applications (+30%), especially involving companies not dedicated to biotechnology: a fact that would seem to confirm the growing role of biotechnology in redefining and renewing the products and processes of many traditional sectors.

The research intensity of the biotech sector is significantly higher than that found for the Italian industry as a whole.

The investments in biotech R&D1 supported by the sector constitute 3.4% of the investments in R&D supported by the entire national production system, even though biotech companies represent only 0.02% of the total Italian companies.
Compared to manufacturing activities, from which the majority of investments in research by national companies originate, those of biotech show a significantly higher incidence of investments in R&D on turnover:
- 4 times for biotech companies in general;
- 9 times for companies dedicated to biotech R&D;
- by as much as 20 times for Italian-capital companies dedicated to biotech R&D.
• The gap recorded for the share of R&D employees out of the total number of employees compared to manufacturing activities is equally wide:
- approximately 7 times for biotech companies in general;
- 10 times for companies dedicated to biotech R&D.

Presentation of the report
Tuesday 6 July (9.30am) Assobiotec and Enea will present the data from the 2021 economic update. The online event is open to companies, stakeholders from the biotech world and journalists.

Download the report
Further documentation
Registrations and information for the event

Read also: National R&D System